1. |
Islami F, Chen W, Yu XQ, et al. Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013. Ann Oncol, 2017, 28(10): 2567-2574.
|
2. |
Wang M, Wang Y, Feng X, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese national cancer center. Int J Infect Dis, 2017, 65: 15-21.
|
3. |
朱健, 陈建国, 张永辉, 等. 启东肝癌早诊早治示范项目的管理与质量控制. 中国肿瘤, 2011, 20(5): 331-335.
|
4. |
Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol, 2014, 28(5): 783-793.
|
5. |
冉建朝, 王乐, 张玥, 等. 中国人群肝癌所致 DALYs 疾病负担: 1990~2016 年长期分析及预测. 中国循证医学杂志, 2018, 18(5): 401-409.
|
6. |
Chan SL, Wong VW, Qin S, et al. Infection and cancer: the case of hepatitis B. J Clin Oncol, 2016, 34(1): 83-90.
|
7. |
Yang HI, Sherman M, Su J, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol, 2010, 28(14): 2437-2444.
|
8. |
Lin YJ, Lee MH, Yang HI, et al. Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients. PLoS One, 2013, 8(4): e61448.
|
9. |
Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol, 2011, 12(6): 568-574.
|
10. |
Lee HW, Ahn SH. Prediction models of hepatocellular carcinoma development in chronic hepatitis B patients. World J Gastroenterol, 2016, 22(37): 8314-8321.
|
11. |
Hann HW, Wan S, Myers RE, et al. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One, 2012; 7(10): e47687.
|
12. |
Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol, 2015, 62(2): 363-370.
|
13. |
Su TH, Hu TH, Chen CY, et al. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int, 2016, 36(12): 1755-1764.
|
14. |
朱立国, 田华, 姜洁, 等. 江苏省 2012-2014 年慢性 HBV 感染者 HBeAg 血清学转换后再逆转的特征分析. 中华流行病学杂志, 2017, 38(1): 43-48.
|
15. |
胡晓云, 孙剑. 我国乙型肝炎长期随访队列建设的现状与展望. 临床肝胆病杂志, 2017, 33(8): 1454-1457.
|
16. |
启东肝癌早诊早治示范基地项目工作进展. 中国肿瘤, 2009, 18(9): 731-734.
|
17. |
严永峰, 王宇婷, 朱陈, 等. 肝癌筛查技术准确性的 Meta 分析. 中国循证医学杂志, 2018, 18(5): 418-427.
|
18. |
石菊芳, 赵琨, 曲春枫, 等. 肝癌筛查相关卫生技术评估. 中国循证医学杂志, 2018, 18(5): 397-400.
|
19. |
van Meer S, de Man RA, Siersema PD, et al. Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies. World J Gastroenterol, 2013, 19(40): 6744-6756.
|
20. |
Cucchetti A, Cescon M, Erroi V, et al. Cost-effectiveness of liver cancer screening. Best Pract Res Clin Gastroenterol, 2013, 27(6): 961-972.
|